Affordable Access

deepdyve-link
Publisher Website

New Rheumatoid Arthritis Treatments for ‘Old’ Patients: Results of a Systematic Review

Authors
  • Caporali, Roberto1, 2
  • Fakhouri, Walid K. H.3
  • Nicolay, Claudia4
  • Longley, Harriet J.3
  • Losi, Serena5
  • Rogai, Veronica5
  • 1 University of Milan,
  • 2 Rheumatology Unit, ASST Gaetano Pini-CTO Hospital, Milan, Italy
  • 3 Eli Lilly and Company,
  • 4 Lilly Deutschland GmbH,
  • 5 Eli Lilly Italy S.p.A.,
Type
Published Article
Journal
Advances in Therapy
Publisher
Springer Healthcare
Publication Date
Jul 23, 2020
Volume
37
Issue
9
Pages
3676–3691
Identifiers
DOI: 10.1007/s12325-020-01435-6
PMID: 32705531
PMCID: PMC7444401
Source
PubMed Central
Keywords
License
Unknown

Abstract

In the last 20 years, new treatments and a new treatment approach (called treat-to-target) have been introduced for rheumatoid arthritis (RA). Consequently, the characteristics of patients with RA participating in clinical trials of the newest therapies should have changed compared with those of patients who participated in clinical trials of older therapies. This is important as patient characteristics may influence patients’ response to drug treatment. To determine whether characteristics of patients with RA have changed over time, we compared the baseline characteristics (e.g. age, gender, disease duration, measures of disease activity, and pain scores) of patients with RA between 22 clinical trials published in 1999–2009 and 18 published in 2010–2017. No significant difference between the two timeframes and no obvious trend over time were observed for any baseline characteristic of patients with RA, including physician and patient measures of disease activity, and patient measures of physical function and pain. Thus, the baseline characteristics of patients with RA participating in clinical trials do not appear to have changed in the last decade despite the introduction of new treatments and the treat-to-target approach. Further research is needed to determine the impact of baseline patient characteristics on patients’ response to RA treatments. Electronic Supplementary Material The online version of this article (10.1007/s12325-020-01435-6) contains supplementary material, which is available to authorized users.

Report this publication

Statistics

Seen <100 times